Ruben Millet
The COVID-19 pandemic has presented a global health crisis, affecting millions of lives worldwide. While most individuals experience mild to moderate symptoms, severe cases can lead to Acute Respiratory Distress Syndrome (ARDS) and multi-organ failure, resulting in mortality. Early identification of patients at risk of severe outcomes is crucial for providing timely interventions and improving survival rates. Recent research has focused on exploring metabolic and lipidomic markers as potential predictors of early mortality in COVID-19 patients. This article examines the significance of these markers in predicting COVID-19-related mortality and their potential implications for clinical practice. Metabolomics is the study of small-molecule metabolites present in biological systems. These metabolites play essential roles in various cellular processes, and their altered levels can reflect changes in the body's physiological state. Similarly, lipidomics focuses on analyzing lipid molecules and their role in cellular function and signaling pathways. In the context of COVID-19, the dysregulation of metabolic and lipidomic pathways has been linked to disease severity and outcomes. Emerging evidence suggests that specific metabolic markers can serve as early indicators of poor prognosis in COVID-19 patients.
分享此文章
English 
Spanish 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 